基于 metionin代谢基因,质瘤中的基因特征的预后预测
Sujin Zhou1, Xianan Zhao1, Shiwei Zhang1
1School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, 510006, Guangzhou, Guangdong Province, China.
BMC medical genomics
|December 7, 2023
概括
一个新的7基因模型通过分析氨酸代谢来预测质瘤存活率,为预测患者预后提供了比成像更方便的替代方案.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 生物化学 生物化学
背景情况:
- 质瘤细胞表现出加快的氨酸代谢,可通过11C-L-氨酸PET扫描检测到.
- 由于11C-L-氨酸的半衰期很短,这限制了它在质瘤监测中的临床实用性.
- 开发基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因.
研究的目的:
- 建立和验证基于 metionin代谢基因的质瘤生存预后模型.
- 调查与已识别的基因签名相关的生物功能和免疫特征.
- 评估整合氨酸代谢基因签名的诺姆图的临床适用性.
主要方法:
- 来自TCGA的质瘤数据集中的29个甲胺代谢基因的分析.
- 使用拉索和考克斯回归分析构建风险模型.
- 在独立导出和验证队列 (CGGA) 中对预后模型的验证.
- 功能丰富分析 (GO,KEGG,GSEA) 和免疫特征分析 (ESTIMATE).
主要成果:
- 在29个 metionin代谢基因中,有25个与质瘤存活率显著相关 (p < 0.05).
- 一个7基因签名显示出强大的预后能力 (C指数=0.83),与预后不佳和整体存活率有关.
- 风险模型与免疫反应和上皮层-介质细胞过渡有关.
- 在培训和验证组中,一个包含签名的名录显示出强大的预后性能.
结论:
- 开发的7基因 metionin代谢特征为预测质瘤存活率提供了一个有前途的工具.
- 这种基于基因的模型增强了对质瘤中 metionin代谢的理解.
- 该模型有可能为精确的治疗策略和改善在质瘤管理中的临床应用提供潜力.
相关概念视频
02:18Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...